Partnerships
KAIMRC Medical Biotechnology Park is launching a set of Innovation Programs dedicated to strategic partnerships with government, academic and industrial entities locally and globally with the aim to:
- Contribute to the ongoing transition of KSA economy from one based on natural resources to one based on knowledge and innovation with special emphasis on medical R&D
- Tackle diseases of highest incidence in the Kingdom of Saudi Arabia with global impact in order to be aligned with the national vision of providing excellent healthcare through innovation.
- Accelerate the set-up of applied Research and ensure a direct impact on patients care by setting up, a world-class medical R&D, biotechnology and biopharmaceutical hub at MNG-HA/KAIMRC.
- Rapidly build one of the world’s leading hubs for precision medicine in KSA.
Collaborations
Signing of an MoU with AstraZeneca in January 2019:
The objective is to develop capacity building and training program as well as develop joint clinical trials for diseases of interest to the Kingdom of Saudi Arabia.
Signing of an MoU with AstraZeneca in January 2019:
The objective is to develop capacity building and training program as well as develop joint clinical trials for diseases of interest to the Kingdom of Saudi Arabia.
Signing of an MoU with Roche in January 2019:
The objective is to develop capacity building and training program as well as develop joint clinical trials for diseases of interest to the Kingdom of Saudi Arabia.
Signing of an MoU with Hammersmith Medical Research Inc. in January 2019:
The objective is to develop capacity building and training program as well as the development of clinical trials management skills and pharmaceutical manufacturing capabilities in the Kingdom of Saudi Arabia.
Signing of an MoU with SABIC in January 2019:
The objective is to develop joint biomedical and health R&D and innovation projects in drug discovery and development.
Signing of an MoU with Moderna in January 2019:
The objective is to develop
……
Signing of an MoU with Pfizer in January 2019:
The objective is to develop
……
Signing of an MoU with Hevolution Foundation in January 2019:
The objective is to develop
……